Galera Therapeutics
Manufacturing · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
45 Liberty Blvd Ste 230, Malvern, Pennsy...Phone Number
(610) 725-1500Website
www.galeratx.comRevenue
$6.3 MillionStock Symbol
GRTXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer. Galera's technology consists of selective small molecule dismutase mimetics that are in late-stage development in patients with cancer. Avasopasem is in development for radiotherapy-induced toxicities, including SOM in patients with head and neck cancer and esophagitis in patients with lung cancer. Avasopasem has been granted FDA Fast Track and Breakthrough Therapy designations for the reduction of SOM induced by radiotherapy, with or without systemic therapy. Galera's second dismutase mimetic product candidate, GC4711, is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer.Explore more
Galera Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Galera Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Galera Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Galera Therapeutics
Click to see if Galera Therapeutics had a recent Job posting/layoffs
Galera Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Galera Therapeutics is spiking on competitors!
Check if Galera Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Galera Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Galera Therapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Galera Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Galera Therapeutics
Compare insights from companies similar to Galera Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Galera Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Galera Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Galera Therapeutics.
Galera Therapeutics Tech Stack
A closer look at the technologies used by Galera Therapeutics
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Earnings
Financial Planning
Earnings
Earnings
Financial Planning
Earnings
Galera Therapeutics News & Media
Director grows Galera (NASDAQ: GRTX) stake via private placement and merger
Galera director Nancy T. Chang reports 8.9M shares, or 5.9% ownership, after investing $499,979 in a 2024 private placement and receiving shares through the Nova merger.[Form 4] Galera Therapeutics, Inc. Insider Trading Activity - Stock Titan
Galera Therapeutics director and 10% owner Nancy T. Chang converted preferred stock into common shares.Galera Therapeutics Updates Preferred Stock Conversion Provisions - The Globe and Mail
Detailed price information for Galera Therapeutics Inc (GRTX) from The Globe and Mail including charting and trades.Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million
Galera Therapeutics Announces Acquisition of Avasopasem and the Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Galera Therapeutics
Sign Up For FreeTo access detailed company insights
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer. Galera's technology consists of selective small molecule dismutase mimetics that are in late-stage development in patie... Read More
